antipsychotic agents

Summary

Summary: Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Top Publications

  1. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
  2. ncbi Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
    Shitij Kapur
    Clarke Division of the Centre for Addiction and Mental Health, 250 College St, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 160:13-23. 2003
  3. ncbi Chlorpromazine equivalent doses for the newer atypical antipsychotics
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychiatry 64:663-7. 2003
  4. ncbi Antipsychotic-induced weight gain: a comprehensive research synthesis
    D B Allison
    Obesity Research Center, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, NY 10025, UDA
    Am J Psychiatry 156:1686-96. 1999
  5. pmc The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 36:71-93. 2010
  6. ncbi Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia
    Effat S Emamian
    The Rockefeller University, Laboratory of Human Neurogenetics, 1230 York Avenue, Box 313, New York, New York 10021, USA
    Nat Genet 36:131-7. 2004
  7. pmc Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis
    Christine Rummel-Kluge
    Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Möhlstr 26, 81675 Munchen, Germany
    Schizophr Res 123:225-33. 2010
  8. ncbi Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    CNS Drugs 19:1-93. 2005
  9. doi Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design
    Roberto Coccurello
    Institute of Neuroscience, National Research Council C N R, Via del Fosso di Fiorano, 64 00143 Roma, Italy
    Pharmacol Ther 127:210-51. 2010
  10. ncbi Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
    Bryan L Roth
    Department of Biochemistry, School of Medicine, Case Western Reserve University, 2109 Adelbert Road, Cleveland, Ohio 44106, USA
    Nat Rev Drug Discov 3:353-9. 2004

Detail Information

Publications343 found, 100 shown here

  1. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  2. ncbi Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia
    Shitij Kapur
    Clarke Division of the Centre for Addiction and Mental Health, 250 College St, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 160:13-23. 2003
    ..The objective of this overview is to link the neurobiology (brain), the phenomenological experience (mind), and pharmacological aspects of psychosis-in-schizophrenia into a unitary framework...
  3. ncbi Chlorpromazine equivalent doses for the newer atypical antipsychotics
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychiatry 64:663-7. 2003
    ..Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed...
  4. ncbi Antipsychotic-induced weight gain: a comprehensive research synthesis
    D B Allison
    Obesity Research Center, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, NY 10025, UDA
    Am J Psychiatry 156:1686-96. 1999
    ..The purpose of this study was to estimate and compare the effects of antipsychotics-both the newer ones and the conventional ones-on body weight...
  5. pmc The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 36:71-93. 2010
    ....
  6. ncbi Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia
    Effat S Emamian
    The Rockefeller University, Laboratory of Human Neurogenetics, 1230 York Avenue, Box 313, New York, New York 10021, USA
    Nat Genet 36:131-7. 2004
    ....
  7. pmc Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis
    Christine Rummel-Kluge
    Klinik und Poliklinik fur Psychiatrie und Psychotherapie der Technischen Universitat Munchen, Klinikum rechts der Isar, Möhlstr 26, 81675 Munchen, Germany
    Schizophr Res 123:225-33. 2010
    ..We conducted a meta-analysis of studies comparing the metabolic side effects of the following SGAs head-to-head: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine...
  8. ncbi Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    CNS Drugs 19:1-93. 2005
    ..trials indicates that weight gain liability varies significantly across the different second generation antipsychotic agents. Clozapine and olanzapine treatment are associated with the greatest risk of clinically significant weight ..
  9. doi Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design
    Roberto Coccurello
    Institute of Neuroscience, National Research Council C N R, Via del Fosso di Fiorano, 64 00143 Roma, Italy
    Pharmacol Ther 127:210-51. 2010
    ..For this reason, recently identified obesogenic and diabetogenic mechanisms are the background on which the present work is built and some novel forthcoming lines of investigation suggested...
  10. ncbi Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
    Bryan L Roth
    Department of Biochemistry, School of Medicine, Case Western Reserve University, 2109 Adelbert Road, Cleveland, Ohio 44106, USA
    Nat Rev Drug Discov 3:353-9. 2004
  11. ncbi Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
    Sandeep T Patil
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Med 13:1102-7. 2007
    ..These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia...
  12. pmc Increasing off-label use of antipsychotic medications in the United States, 1995-2008
    G C Alexander
    Department of Medicine, University of Chicago Hospitals, Chicago, Illinois, USA
    Pharmacoepidemiol Drug Saf 20:177-84. 2011
    ..We also quantified use without U.S. Food and Drug Administration approval (off-label use) and off-label use with compendium data suggesting an uncertain evidence base...
  13. pmc Genomewide association study of movement-related adverse antipsychotic effects
    Karolina Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Biol Psychiatry 67:279-82. 2010
    ..Understanding individual differences in the development of extrapyramidal side effects (EPS) as a response to antipsychotic therapy is essential to individualize treatment...
  14. ncbi Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Mol Psychiatry 13:27-35. 2008
    ....
  15. doi The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
    Chao Deng
    Centre for Translational Neuroscience, School of Health Sciences, University of Wollongong, Wollongong, 2522, NSW, Australia
    Prog Neuropsychopharmacol Biol Psychiatry 34:1-4. 2010
    ..In addition, atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor...
  16. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  17. doi Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada
    Bipolar Disord 11:225-55. 2009
    ..Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder...
  18. ncbi H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs
    Wesley K Kroeze
    Department of Biochemistry, RM W463, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4935, USA
    Neuropsychopharmacology 28:519-26. 2003
    ....
  19. pmc Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs
    Nancy C Andreasen
    Mental Health Clinical Research Center, Department of Psychiatry, Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1057, USA
    Biol Psychiatry 67:255-62. 2010
    ..An expert consensus group has published charts of equivalent doses for various antipsychotic medications for first- and second-generation medications. These charts were used in this study...
  20. ncbi Risperidone in children with autism and serious behavioral problems
    James T McCracken
    University of California, Los Angeles, USA
    N Engl J Med 347:314-21. 2002
    Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with ..
  21. doi Antipsychotic polypharmacy in schizophrenia: benefits and risks
    Thomas R E Barnes
    Division of Experimental Medicine, Centre for Mental Health, Imperial College London, Charing Cross Campus, London, UK
    CNS Drugs 25:383-99. 2011
    ..Further, their prescription for each patient should be in the context of an individual trial, with monitoring of the clinical response and adverse effects, and appropriate physical health monitoring...
  22. doi Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Lancet 373:31-41. 2009
    ....
  23. ncbi Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
    D Robinson
    Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 56:241-7. 1999
    ..We examined relapse after response to a first episode of schizophrenia or schizoaffective disorder...
  24. pmc Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs
    Miguel Fribourg
    Department of Structural and Chemical Biology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cell 147:1011-23. 2011
    ..These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia...
  25. ncbi Schizophrenia
    Kim T Mueser
    New Hampshire Dartmouth Psychiatric Research Center, Department of Psychiatry, Dartmouth
    Lancet 363:2063-72. 2004
    ....
  26. pmc The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
    ..To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States...
  27. ncbi The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
    Schizophr Res 68:283-97. 2004
    ..76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement...
  28. doi Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms
    Gavin P Reynolds
    Department of Psychiatry, Queen s University Belfast, Belfast BT9 7BL, UK
    Pharmacol Ther 125:169-79. 2010
    ..Understanding the pharmacology of metabolic consequences of current antipsychotic drug treatment is clearly the key to developing improved pharmacotherapies that avoid these problematic and limiting adverse effects...
  29. ncbi Metabolomic mapping of atypical antipsychotic effects in schizophrenia
    R Kaddurah-Daouk
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Mol Psychiatry 12:934-45. 2007
    ..A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes...
  30. doi Intervention in individuals at ultra-high risk for psychosis: a review and future directions
    Patrick D McGorry
    Centre for Youth Mental Health, Orygen Youth Health Research Centre, University of Melbourne, Victoria, Australia
    J Clin Psychiatry 70:1206-12. 2009
    ..This article reviews intervention research in the ultra-high-risk phase of psychotic disorders...
  31. pmc Atypical antipsychotic drugs and the risk of sudden cardiac death
    Wayne A Ray
    Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville 37212, USA
    N Engl J Med 360:225-35. 2009
    ..However, less is known regarding the cardiac safety of the atypical antipsychotic drugs, which have largely replaced the older agents in clinical practice...
  32. pmc Reward processing in schizophrenia: a deficit in the representation of value
    James M Gold
    Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Schizophr Bull 34:835-47. 2008
    ..In contrast, patients often (but not always) approach normal performance levels on the slow learning achieved by the integration of reinforcement signals over many trials, thought to be mediated by the basal ganglia...
  33. ncbi Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy
    Shitij Kapur
    Centre for Addiction and Mental Health, Clarke Site 250 College Street Toronto, Ontario Canada M5R 1T8
    J Pharmacol Exp Ther 305:625-31. 2003
    ..The study provides a rationale as well as clinically comparable dosing regimens for animal studies and raises questions about the inferences drawn from previous studies that have used doses unrepresentative of the clinical situation...
  34. pmc Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, 75 59 263rd St, Glen Oaks, NY 11004, USA
    JAMA 302:1765-73. 2009
    ..Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication...
  35. doi Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity
    Tadashi Ishibashi
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Suita, Osaka, Japan
    J Pharmacol Exp Ther 334:171-81. 2010
    ..These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects...
  36. ncbi Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Terry E Goldberg
    Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 64:1115-22. 2007
    ..However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects...
  37. ncbi Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents
    Christoph U Correll
    The Zucker Hillside Hospital, Psychiatry Research, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    J Am Acad Child Adolesc Psychiatry 45:771-91. 2006
    ..Endocrine and metabolic adverse effects are among the most concerning adverse effects of commonly used psychotropic medications...
  38. doi Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
    Marc De Hert
    University Psychiatric Center, Catholic University Leuven, Leuvensesteenweg 517, 3070 Kortenberg, Belgium marc de hert uc kortenberg be
    Nat Rev Endocrinol 8:114-26. 2012
    ..b>Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both ..
  39. doi Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
    T A P Lett
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Mol Psychiatry 17:242-66. 2012
    ..More research is required before genetically informed, personalized medicine can be applied to antipsychotic treatment; nevertheless, inroads have been made towards assessing genetic liability and plausible clinical application...
  40. doi A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychopharmacol 31:349-55. 2011
    ..Additional efficacy, safety, and tolerability testing are needed...
  41. doi Tardive dyskinesia and new antipsychotics
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Curr Opin Psychiatry 21:151-6. 2008
    ..To provide an update on tardive dyskinesia rates in patients treated with first-generation or second-generation antipsychotics in studies published since the last systematic review in 2004...
  42. doi Long-acting risperidone and oral antipsychotics in unstable schizophrenia
    Robert A Rosenheck
    Veterans Affairs VA New England Mental Illness, Research Education and Clinical Center, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    N Engl J Med 364:842-51. 2011
    ....
  43. ncbi Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
    Michael F Green
    Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, USA
    Schizophr Res 72:41-51. 2004
    ..These steps are apt to have important implications for clinical trials of cognition-enhancing agents in schizophrenia...
  44. doi Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat
    G C Smith
    Department of Molecular Medicine and Pathology and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Diabetologia 51:2309-17. 2008
    ..We hypothesised that, in addition to the insulin resistance associated with the obesity, the SGAs might have acute effects on glucose metabolism that could contribute to the derangements in glucose metabolism...
  45. ncbi Antipsychotic medications: metabolic and cardiovascular risk
    John W Newcomer
    Department of Psychiatry, Center for Clinical Studies, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:8-13. 2007
    ..Various strategies for monitoring cardiometabolic risk factors in patients with mental illness are discussed in this review...
  46. doi Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence
    Corrado Barbui
    Section of Psychiatry and Clinical Psychology, Department of Medicine and Public Health, University of Verona, Verona, Italy
    Psychopathology 42:311-7. 2009
    ..Factors influencing patient and clinician perspectives in the assessment of medication adherence have never been compared...
  47. ncbi Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat
    Masafumi Kodama
    Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    Biol Psychiatry 56:570-80. 2004
    ..There has been increasing evidence that atypical antipsychotics are effective in the treatment of mood disorders or for augmenting 5-hydroxytryptamine selective reuptake inhibitors for treatment-resistant depression...
  48. pmc Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys
    Glenn T Konopaske
    Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Biol Psychiatry 63:759-65. 2008
    ..Consequently, in this study we sought to determine whether the lower glial cell number was due to fewer oligodendrocytes as opposed to lower numbers of astrocytes...
  49. pmc Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
    ....
  50. ncbi GABA-based therapeutic approaches: GABAA receptor subtype functions
    Uwe Rudolph
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland, and Laboratory of Genetic Neuropharmacology, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Curr Opin Pharmacol 6:18-23. 2006
    ..Thus, a new pharmacology based on GABAA receptor subtype-specific actions is emerging...
  51. ncbi Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  52. ncbi Predictors of noncompliance in patients with schizophrenia
    Diana O Perkins
    University of North Carolina Chapel Hill, Department of Psychiatry, Chapel Hill 27599 7160, USA
    J Clin Psychiatry 63:1121-8. 2002
    ..The health belief model views noncompliance as a decision made by the patient, arrived at after weighing the perceived risks and benefits of treatment...
  53. ncbi Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
    S Miyamoto
    Department of Neuropsychiatry, St Marianna University School of Medicine, Kawasaki, Japan
    Mol Psychiatry 10:79-104. 2005
    ....
  54. doi Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
    Diego Novick
    Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Psychiatry Res 176:109-13. 2010
    ..Also, reversal of some risk factors may improve adherence. Non-adherence is associated with a range of poorer long-term outcomes, with clinical and economic implications...
  55. pmc Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia
    Dominique Arion
    Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Biol Psychiatry 62:711-21. 2007
    ..Schizophrenia is characterized by complex gene expression changes. The transcriptome alterations in the prefrontal cortex have been the subject of several recent postmortem studies that yielded both convergent and divergent findings...
  56. doi Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
    Mahesh N Samtani
    Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
    CNS Drugs 25:829-45. 2011
    ..Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic...
  57. doi Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    Am J Psychiatry 168:957-67. 2011
    ..The study was designed to evaluate the short-term efficacy and safety of lurasidone in the treatment of acute schizophrenia...
  58. pmc Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia
    Yael Piontkewitz
    Department of Psychology, Tel Aviv University, Tel Aviv, Israel
    Schizophr Bull 37:1257-69. 2011
    ..Furthermore, highly selective 5HT(2A) receptor antagonists may be promising targets for psychosis prevention...
  59. doi Trends in antipsychotic use in dementia 1999-2007
    Helen C Kales
    Veterans Affairs Health Services Researchand Development Center for Clinical Management Research, Serious Mental Illness Treatment, Resource, and Evaluation Center, Ann Arbor, Michigan, USA
    Arch Gen Psychiatry 68:190-7. 2011
    ..Concerns about their use began to emerge in 2002, and in 2005, the US Food and Drug Administration warned that use of atypical antipsychotics in dementia was associated with increased mortality...
  60. ncbi The case for long-acting antipsychotic agents in the post-CATIE era
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
    Acta Psychiatr Scand 115:260-7. 2007
    Long-acting antipsychotic agents were developed to promote treatment compliance in patients requiring maintenance treatment for schizophrenia.
  61. doi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
    ..The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia...
  62. doi Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
    Srihari Gopal
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Int Clin Psychopharmacol 25:247-56. 2010
    ..than placebo (>or=5% difference) were headache, vomiting, extremity pain, and injection site pain. Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses tested were tolerable...
  63. pmc Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
    V L Albaugh
    Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Mol Psychiatry 16:569-81. 2011
    ..Collectively, these results suggest that olanzapine exerts several metabolic effects that together favor increased accumulation of fuel into adipose tissue, thereby increasing adiposity...
  64. ncbi Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals
    Dennis Velakoulis
    Melbourne Neuropsychiatry Centre and Department of Psychiatry, University of Melbourne, Australia
    Arch Gen Psychiatry 63:139-49. 2006
    ..These studies have been limited by small samples and the absence of patients early in the course of illness...
  65. pmc Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis
    Nicolas A Crossley
    Division of Psychological Medicine, Institute of Psychiatry PO 67, De Crespigny Park, London SE58AF
    Br J Psychiatry 196:434-9. 2010
    ..There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis...
  66. doi The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression
    Heinz Grunze
    Newcastle University, RVI, Division of Psychiatry, Institute of Neuroscience, Newcastle upon Tyne, UK
    World J Biol Psychiatry 11:81-109. 2010
    ..Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults...
  67. doi Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
    David Hough
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
    Schizophr Res 116:107-17. 2010
    ..We assessed efficacy and tolerability of the injectable atypical antipsychotic paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia...
  68. pmc Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions
    P R Corlett
    Brain Mapping Unit, Department of Psychiatry, University of Cambridge, School of Clinical Medicine, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    Brain 130:2387-400. 2007
    ..Our results support a neurobiological theory of delusion formation that implicates aberrant prediction-error signalling, disrupted attentional allocation and associative learning in the formation of delusional beliefs...
  69. doi A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Am J Psychiatry 166:152-63. 2009
    ..The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head...
  70. doi Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
    G M Goodwin
    University Department of Psychiatry, Warneford Hospital, Oxford, UK
    J Psychopharmacol 23:346-88. 2009
    ..The strength of supporting evidence was rated. The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use of medicines in treatment of episodes, relapse prevention and stopping treatment...
  71. ncbi A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone
    Rocio Perez-Iglesias
    Department of Psychiatry, Marques de Valdecilla University Hospital, University of Cantabria, Santander, Spain
    J Clin Psychiatry 68:1733-40. 2007
    ..This study examined the main metabolic side effects induced by antipsychotic treatment in a cohort of first-episode drug-naive subjects...
  72. doi Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension
    Andreas Tzimos
    Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece
    Am J Geriatr Psychiatry 16:31-43. 2008
    ..The study was not powered to show statistical differences...
  73. doi Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder
    Wan Seok Seo
    Department of Neuropsychiatry, Yeungnam University, Daegu, Korea
    J Child Adolesc Psychopharmacol 18:197-205. 2008
    ....
  74. ncbi An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders
    Hanik K Yoo
    Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Clin Psychiatry 68:1088-93. 2007
    ....
  75. ncbi A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia
    Michael R Law
    Department of Ambulatory Care and Prevention, Harvard Medical School, and Harvard Pilgrim Health Care, Boston, Mass 02215, USA
    J Clin Psychiatry 69:47-53. 2008
    ..However, such analyses typically measure adherence averaged over long time periods. We investigated the temporal relationship between nonadherence and hospitalization risk using a daily measure of medication availability...
  76. ncbi Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics
    Georg Juckel
    Department of Psychiatry, Charite University Medical Center, Campus Charité Mitte CCM, Schumannstr 20 21, Berlin 10117, Germany
    Psychopharmacology (Berl) 187:222-8. 2006
    ..Dysfunction of the dopaminergic reward system may contribute to negative symptoms in schizophrenia...
  77. ncbi The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
    Shaun Jordan
    Neuroscience Department, Maryland Research Laboratories, Otsuka Maryland Research Institute, 9900 Medical Center Drive, Rockville, MD 20850, USA
    Eur J Pharmacol 441:137-40. 2002
    ..Combined with previous studies demonstrating the potent partial agonism of aripiprazole at dopamine D2 receptors, this study suggests aripiprazole is the first dopamine-serotonin system stabilizer...
  78. ncbi Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia...
  79. ncbi Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt Medical Center, Nashville, TN, USA
    J Clin Psychiatry 69:817-29. 2008
    ..To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily...
  80. doi A randomised controlled trial of cognitive behaviour therapy for psychosis in a routine clinical service
    Emmanuelle Peters
    Department of Psychology, Kings College London, Institute of Psychiatry, De Crespigny Park, London, UK
    Acta Psychiatr Scand 122:302-18. 2010
    ..To evaluate cognitive behaviour therapy for psychosis (CBTp) delivered by non-expert therapists, using CBT relevant measures...
  81. doi Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder
    Donald C Goff
    Schizophrenia Program, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 71:20-6. 2010
    ....
  82. doi Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
    S Gopal
    Johnson and Johnson PRD, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, USA
    Curr Med Res Opin 26:377-87. 2010
    ..This article overviews the recommended dosing strategies for the treatment of schizophrenia patients using the recently FDA-approved once-monthly long-acting injectable atypical antipsychotic, paliperidone palmitate...
  83. doi Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 4:251-7. 2011
    ..Lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the ECG QT interval...
  84. pmc Past and present progress in the pharmacologic treatment of schizophrenia
    John M Kane
    Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 71:1115-24. 2010
    ....
  85. pmc Effect of second-generation antipsychotics on cognition: current issues and future challenges
    S Kristian Hill
    Center for Cognitive Medicine M C 913, University of Illinois at Chicago, 912 South Wood Street, Suite 235, Chicago, IL 60612, USA
    Expert Rev Neurother 10:43-57. 2010
    ....
  86. pmc Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study
    Gholson J Lyon
    New York University Child Study Center, New York, New York 10016, USA
    J Child Adolesc Psychopharmacol 19:623-33. 2009
    ..The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD)...
  87. ncbi Neurological complications of psychiatric drugs: clinical features and management
    Peter M Haddad
    Neuroscience and Psychiatry Unit, School of Psychiatry and Behavioural Sciences, University of Manchester, Manchester, UK
    Hum Psychopharmacol 23:15-26. 2008
    ..Their occurrence needs to be balanced against the benefits of psychiatric drugs in terms of efficacy and improved quality of life in a range of disorders...
  88. doi Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory
    M S Barr
    Schizophrenia Program, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Schizophr Res 121:146-52. 2010
    ..These findings may provide important insights into the pathophysiology underlying WM deficits, its relationship to negative symptoms and may represent a potential neurobiological marker for cognitive enhancing strategies in SCZ...
  89. doi A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder
    Eduard Vieta
    Institute of Neuroscience, University of Barcelona Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain
    Bipolar Disord 12:230-43. 2010
    ..To evaluate the antimanic efficacy and safety of paliperidone extended-release (ER) tablets in patients with bipolar I disorder...
  90. doi Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study
    John W Devlin
    Northeastern University School of Pharmacy, Boston, MA, USA
    Crit Care Med 38:419-27. 2010
    ..To compare the efficacy and safety of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol...
  91. doi Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials
    Claudia Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 127:83-92. 2011
    ..Non-adherence is a major problem in the treatment of schizophrenia. Depot antipsychotic drugs are thought to reduce relapse rates by improving adherence, but a systematic review of long-term studies in outpatients is not available...
  92. doi Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    J Affect Disord 126:358-65. 2010
    ..We report the results of long-term treatment with asenapine in patients with bipolar I disorder...
  93. ncbi Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review
    Viktoria Simon
    Department of Psychiatry and Psychotherapy, Semmelweis University Budapest, Hungary
    J Clin Psychiatry 70:1041-50. 2009
    ..Numerous publications have provided evidence for clinically important metabolic adverse effects of antipsychotics, but there is no systematic evaluation as to whether weight gain and other metabolic changes are dose dependent...
  94. doi Management of behavioral problems in Alzheimer's disease
    Serge Gauthier
    Alzheimer s Disease and Related Disorders Unit, McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Canada
    Int Psychogeriatr 22:346-72. 2010
    ..Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class...
  95. doi Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories
    Stephen Z Levine
    Bar Ilan University, Ramat Gan, Israel
    Biol Psychiatry 68:86-92. 2010
    ..To extend the early treatment response literature, this article aims to quantify the extent of heterogeneity and describe the characteristics of treatment response trajectories in schizophrenia...
  96. doi Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008
    ..To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients with schizophrenia...
  97. doi Bipolar depression: overview and commentary
    Ross J Baldessarini
    Harvard Medical School, McLean Hospital, Belmont, MA, USA
    Harv Rev Psychiatry 18:143-57. 2010
    ..Interest in recognizing bipolar depression and seeking more effective, specific, and safer treatments for it are growing...
  98. doi Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial
    Mette Bertelsen
    Bispebjerg Hospital, Department of Psychiatry, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark
    Arch Gen Psychiatry 65:762-71. 2008
    ..Intensive early treatment for first-episode psychosis has been shown to be effective. It is unknown if the positive effects are sustained for 5 years...
  99. pmc Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
    Rune A Kroken
    Division of Psychiatry, Haukeland University Hospital, PO Box 23, N 5812, Bergen, Norway
    BMC Psychiatry 9:24. 2009
    ..The objective of this study was to evaluate the practice of treatment of schizophrenic patients with antipsychotics at discharge from acute inpatient settings at a national level...
  100. pmc Trajectories and antecedents of treatment response over time in early-episode psychosis
    Stephen Z Levine
    Bar Ilan University, Ramat Gan, Israel
    Schizophr Bull 36:624-32. 2010
    ..The current study aims to quantify the extent of heterogeneity in trajectories of treated symptom severity in early-episode psychosis and their antecedents...
  101. pmc Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Bull 34:1163-71. 2008
    ..This study assessed the predictive accuracy of early nonresponse to treatment and its clinical, functional, and economic ramifications in the naturalistic treatment of predominately chronic outpatients treated for schizophrenia...

Research Grants81

  1. Sedative Hypnotic Use by the Mentally Ill: A Medicaid Prescription Policy Study
    Judy Zerzan; Fiscal Year: 2009
    ....
  2. Medicare Drug Benefits and High Cost Medications: Antipsychotics Under Part D
    Vicki Fung; Fiscal Year: 2011
    ....
  3. Endogenous Kynurenic Acid Modulates Prefrontal ACh Levels and Cognitive Behavior
    Robert Schwarcz; Fiscal Year: 2010
    ....
  4. MOTOR EFFECTS OF ATYPICAL ANTIPSYCHOTICS
    John Salamone; Fiscal Year: 2003
    ..Taken together, the results of these experiments will help to identify the pharmacological characteristics and brain circuits that underlie the motor effects of clozapine. ..
  5. Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
    Karen L Teff; Fiscal Year: 2010
    ..Findings from these studies will have important clinical relevance to the treatment of schizophrenia. ..
  6. Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
    Karen Teff; Fiscal Year: 2009
    ..Findings from these studies will have important clinical relevance to the treatment of schizophrenia. ..
  7. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2007
    ..This information will help to provide a more rational basis for making treatment decisions concerning children and adolescents who may benefit from treatment with an antipsychotic. ..
  8. MECHANISMS OF CARDIOTOXICITY OF ANTIPSYCHOTIC DRUGS
    David Flockhart; Fiscal Year: 2001
    ..3) To determine if antipsychotic agents that are found to be potentially cardiotoxic in vitro have clinical electrocardiac effects at the doses ..
  9. Deconstructing Clozapine: Toward Medication for Alcoholism in Schizophrenia
    Alan I Green; Fiscal Year: 2010
    ....
  10. Antipsychotic Drugs and Maternal Behavior: A Preclinical Investigation
    Ming Li; Fiscal Year: 2007
    ....
  11. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
    Elaine R Peskind; Fiscal Year: 2010
    ..Prazosin blocks the excessive brain adrenaline arousal that contributes to agitation in AD and both therapeutic and tolerability results of our prazosin feasibility study are very promising. ..
  12. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
    Elaine Peskind; Fiscal Year: 2009
    ..Prazosin blocks the excessive brain adrenaline arousal that contributes to agitation in AD and both therapeutic and tolerability results of our prazosin feasibility study are very promising. ..
  13. BIOPHYSICAL STUDY OF ANTIPSYCHOTICS BEHAVIORAL EFFECTS
    Stephen Fowler; Fiscal Year: 2003
    ....
  14. Dopamine action in pancreatic islet function
    David W Piston; Fiscal Year: 2010
    ....
  15. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. ..
  16. Comparative Safety of Atypical Antipsychotics in High-Risk US Children with ADHD
    David M Rubin; Fiscal Year: 2010
    ....
  17. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. ..
  18. Contribution of cell cycle processes to myelin deficits in schizophrenia
    Vahram Haroutunian; Fiscal Year: 2009
    ..Published results from us and others suggest that antipsychotic agents can influence OMR gene expression, but the direction of effect is unclear and how these pharmacological ..
  19. NEUROTENSIN--AN ENDOGENOUS NEUROLEPTIC LIKE PEPTIDE
    Charles Nemeroff; Fiscal Year: 1999
    ..These studies will provide novel information concerning the role of NT systems in the mechanism of action of antipsychotic drugs, and in the pathophysiology of schizophrenia. ..
  20. Negative symptoms of schizophrenia: animal models
    Athina Markou; Fiscal Year: 2009
    ....
  21. Negative symptoms of schizophrenia: animal models
    Athina Markou; Fiscal Year: 2010
    ....
  22. Treatment of Psychotic Disorders in Youth
    Linmarie Sikich; Fiscal Year: 2006
    ....
  23. Serotonin Glutamate Interactions in Prefrontal Cortex
    Gerard Marek; Fiscal Year: 2001
    ..As such, this multi-disciplinarian study may provide new strategies to develop novel antidepressant treatments that would be more efficacious than simply blocking 5-HT2A receptors. ..
  24. Antipsychotic Influence on Altered MTL Neuronal Activity in Schizophrenia
    Carol Tamminga; Fiscal Year: 2009
    ..We propose to test the elements of this model with in vivo brain imaging using measures of basal activity and relational memory probes, correlating alterations in neural activity with characteristics of the illness. ..
  25. Molecular basis of atypical antipsychotic drugs-induced weight gain
    Sangwon F Kim; Fiscal Year: 2010
    ..Hence, it is upmost importance to identify the molecular mechanism of how AAPDs lead to an excessive weight gain. ..
  26. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan Green; Fiscal Year: 2009
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  27. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan I Green; Fiscal Year: 2010
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  28. Antipsychotics and Mortality in Older Patients
    HELEN KALES; Fiscal Year: 2009
    ..our prior work to examine further critical questions including: 1) comparing mortality risks for individual antipsychotic agents in older patients both with and without dementia diagnoses in the 12 months following a new antipsychotic ..
  29. Antipsychotics and Mortality in Older Patients
    HELEN KALES; Fiscal Year: 2007
    ..our prior work to examine further critical questions including: 1) comparing mortality risks for individual antipsychotic agents in older patients both with and without dementia diagnoses in the 12 months following a new antipsychotic ..